Influence of achieved low-density lipoprotein cholesterol level with atorvastatin therapy on stabilization of coronary plaques: Sub-analysis of the TWINS study

Circulation Journal

Volumn 76, Issue 5, 2012, Pages 1197-1202

  Okada, Katsuki ^a   Ueda, Yasunori ^a   Takayama, Tadateru ^b   Honye, Junko ^c   Komatsu, Sei ^d   Yamaguchi, Osamu ^e   Li, Yuxin ^b   Yajima, Junji ^f   Takazawa, Kenji ^g   Nanto, Shinsuke ^e   Saito, Satoshi ^b   Hirayama, Atsushi ^b   Kodama, Kazuhisa ^d  

^a OSAKA POLICE HOSPITAL   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Fuchu Keijin kai Hospital   (Japan)

^d Amagasaki Central Hospital   (Japan)

^e OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f THE CARDIOVASCULAR INSTITUTE   (Japan)

^g TOKYO MEDICAL UNIVERSITY HACHIOJI MEDICAL CENTER   (Japan)

Author keywords

Angioscopy; Atorvastatin; Stabilization of coronary plaque; Yellow plaque

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANGIOSCOPY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY PLAQUE; DRUG DOSE INCREASE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY VESSELS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; PYRROLES; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84860193511     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0966     Document Type: Article

References (18)

1. Hirayama A, Saito S, Ueda Y, Takayama T, Honye J, Komatsu S, et al. Qualitative and quantitative changes in coronary plaque associated with atorvastatin therapy. Circ J 2009; 73: 718-725.
2. Asakura M, Ueda Y, Yamaguchi O, Adachi T, Hirayama A, Hori M, et al. Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: An angioscopic study. J Am Coll Cardiol 2001; 37: 1284-1288.
3. Ueda Y, Ohtani T, Shimizu M, Hirayama A, Kodama K. Assessment of plaque vulnerability by angioscopic classification of plaque color. Am Heart J 2004; 148: 333-335.
4. Masumura Y, Ueda Y, Matsuo K, Akazawa Y, Nishio M, Hirata A, et al. Frequency and location of yellow and disrupted coronary plaques in patients as detected by angioscopy. Circ J 2011; 75: 603-612.
5. Hong YJ, Jeong MH, Hachinohe D, Ahmed K, Choi YH, Cho SH, et al. Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis. Circ J 2011; 75: 398-406.
6. Ueda Y, Asakura M, Yamaguchi O, Hirayama A, Hori M, Kodama K. The healing process of infarct-related plaques: Insights from 18 months of serial angioscopic follow-up. J Am Coll Cardiol 2001; 38: 1916-1922.
7. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239.
8. Kubo T, Imanishi T, Takarada S, Kuroi A, Ueno S, Yamano T, et al. Implication of plaque color classification for assessing plaque vulnerability: A coronary angioscopy and optical coherence tomography investigation. J Am Coll Cardiol Interv 2008; 1: 74-80.
9. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.
10. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. JAMA 2005; 294: 2437-2445.
11. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004; 291: 1071-1080.
12. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006; 295: 1556-1565.
13. Ray KK, Cannon CP, Cairns R, Morrow DA, Rifai N, Kirtane AJ, et al. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005; 46: 1417-1424.
14. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003; 108: 1560-1566.
15. Stefanadis C, Toutouzas K, Tsiamis E, Vavuranakis M, Tsioufis C, Stefanadi E, et al. Relation between local temperature and C-reactive protein levels in patients with coronary artery disease: Effects of atorvastatin treatment. Atherosclerosis 2007; 192: 396-400.
16. Takano M, Mizuno K, Yokoyama S, Seimiya K, Ishibashi F, Okamatsu K, et al. Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin: Serial evaluation by coronary angioscopy. J Am Coll Cardiol 2003; 42: 680-686.
17. Kodama K, Komatsu S, Ueda Y, Takayama T, Yajima J, Nanto S, et al. Stabilization and regression of coronary plaques treated with pitavastatin proven by angioscopy and intravascular ultrasound: The TOGETHAR trial. Circ J 2010; 74: 1922-1928.
18. Hirayama A, Saito S, Ueda Y, Takayama T, Honye J, Komatsu S, et al. Plaque-stabilizing effect of atorvastatin is stronger for plaques evaluated as more unstable by angioscopy and intravenous ultrasound. Circ J 2011; 75: 1448-1454.